Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo

Recruiting now · Not applicable

Conditions studied: Vitiligo

In brief

To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.

Key facts

Study ID

NCT07187882

Run by

Peking University People's Hospital

People needed

30

Starts

2024-04-25

Expected to finish

2025-12-31

Last updated by the study team

2025-09-23

Who can join

Age: 8 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition)
• Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
• BSA≥5%
• Sign the informed consent and be willing to undergo surgical treatment
• 8-65 years old, both genders

You may not qualify if…

• Severe visceral or infectious disease not suitable for surgical treatment
• Tendency toward keloid formation
• Coagulation defects
• Unable to complete follow-up on time

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.